[Extension of beta-lactamases producing bacteria is a worldwide concern].
Since 2000's, community extended-spectrum beta-lactamases (ESBL) producing bacteria have spread worldwide, i.e. mostly Escherichia coli that produce ESBL such as CTX-M enzymes. Previous cephalosporins and fluoroquinolones usage are the two most frequent risk factors identified in patients that harbor ESBL-producing bacteria. In addition surveys have shown an alarming trend of associated resistance to others classes of antimicrobial agents among isolates. The emergence of ESBL-producing isolates limits the therapeutic options considerably. For serious systemic infections caused by ESBL-producing bacteria, carbapenems should be regarded as drugs of choice. Preventing the spread and appropriately managing these infections caused by community acquired ESBL producing bacteria have become mandatory.
Zahar
Jean-Ralph
JR
Université Paris Descartes, CHU Necker-Enfants-Malades, APHP, microbiologie- hygiène hospitalière, 149, rue de Sèvres, 75743 Paris, France. jean-ralph.zahar@nck.aphp.fr
Bille
Emmanuelle
E
Schnell
David
D
Lanternier
Fanny
F
Mechai
Frédéric
F
Masse
Virginie
V
Nassif
Xavier
X
Lortholary
Olivier
O
D001419:Bacteria / Q000201:enzymology* / Q000472:pathogenicity; D001424:Bacterial Infections / Q000453:epidemiology; D004926:Escherichia coli / Q000201:enzymology; D004927:Escherichia coli Infections / Q000453:epidemiology*; D006801:Humans; D007710:Klebsiella Infections / Q000453:epidemiology; D007711:Klebsiella pneumoniae / Q000201:enzymology; D001618:beta-Lactamases / Q000096:biosynthesis*
D001618:beta-Lactamases